

## Supplementary Online Content

Jayadevappa R, Chhatre S, Malkowicz SB, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. *JAMA Netw Open*. 2019;2(7):e196562. doi:10.1001/jamanetworkopen.2019.6562

**eTable 1.** Diagnosis and Procedure Codes

**eTable 2.** Association Between ADT and Diagnosis of Alzheimer's or Dementia (Comorbidity Score Subgroups)

**eTable 3.** Association Between ADT and Diagnosis of Alzheimer's or Dementia (Treatment Type Subgroups)

**eTable 4.** Association Between ADT and Diagnosis of Alzheimer's or Dementia (Cancer Stage)

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable1: Diagnosis and procedure codes

|   | ICD 9 dxs code                                       | ICD 9 procedure code   | HCPCS/CPT code  |
|---|--|--|---|
| <b>Diagnosis</b>  |  |  |   |
| Prostate cancer dx  | 185  |  |   |
| Alzheimer   | 3310   |  |   |
| Dementia  | 290, 29420<br>29411, 29410,<br>29282, 2912,<br>29421 |  |   |
| <b>Treatment</b>  |  |  |   |
| Hormone (androgen deprivation therapy or ADT)   | V07.59   |  | C9216, C9430, G0356, G9132, J0128, J1050, J1051, J1950, J3315, J9165, J9202, J9217-J9219, S0165, S0175, S9560   |
| Orchiectomy   |  | 62.3, 62.4, 62.41, 62.42   | 54520, 54521, 54522, 54530, 54535,  |
| Surgery<br>Radical prostatectomy<br>Laparoscopic (radical prostatectomy, Robotic-assisted laparoscopic radical prostatectomy) |  | 17.42, 40.1, 40.2, 40.3, 40.5, 40.53, 40.59, 60.21, 60.29, 60.2-60.6, 60.51-60.59, 60.61, 60.62, 60.69 | 54690, 55810, 55812, 55815, 55821, 55831, 55840, 55842, 55845, 55866, 55899, S2900  |
| Cryosurgery (cryotherapy/ cryoablation)   |  |  | 55873   |
| Radiation : EBRT  | V58.0, V66.1, V67.1                                  | 60.99, 92.2, 92.20, 92.21-92.29, 92.3, 92.30-92.39, 92.4, 92.41  | 0073T, 0082T, 0182T, 0197T, 55860, 55862, 55865, 55875, 55876, 61793, 76872, 76873, 76965, 77261-79999, C1715, C1717, C2638-C2641, C2698, C2699, G0173, G0251, G0256, G0261, G0339, G0340, G0458, G6003, G6005, G6006, G6015, Q3001, S8049; Revenue center codes 0330 or 0333, 0339 or 0342 |
| Radiation: brachytherapy  |  |  | 0182T, 77750-77799, C1715, C1716, C1717, C1719, C2616, C2634-C2645, C2698, C2699, G0458, Q3001  |
| Chemo tx  | V58.1<br>V66.2, V67.2                                | 99.25  | 95990, 95991, 96400-96549, 96530, J0640, J2405, J8520 - J9999 K0415, K0416, Q0083-Q0085, Q0179, S0177, S0181 Revenue center codes 0331, 0332, or 0335; For 2005 only, use these G0355-G0363, G9021-G9032  |

eTable2: Association between ADT and diagnosis of Alzheimer’s or dementia (comorbidity score subgroups). Hazard ratio represent the comparison between patients with ADT (within 24 months of diagnosis) and those without ADT - sub groups of comorbidity score

| Model                                       | Comorbidity score    |                      |                      |                      |                      |                      |
|---|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
|   | Zero                 |                      | 1-2                  |                      | >2                   |                      |
|   | Alzheimer’s HR (CI)  | Dementia HR (CI)     | Alzheimer’s HR (CI)  | Dementia HR (CI)     | Alzheimer’s HR (CI)  | Dementia HR (C)      |
| <b>Unadjusted</b>                           |                      |                      |                      |                      |                      |                      |
|   | 1.61<br>(1.55, 1.67) | 1.65<br>(1.60, 1.69) | 1.09<br>(1.02, 1.16) | 1.14<br>(1.09, 1.19) | 0.92<br>(0.77, 1.09) | 0.91<br>(0.80, 1.03) |
| <b>Propensity score adjusted * (IPTW)**</b> |                      |                      |                      |                      |                      |                      |
|   | 1.22<br>(1.17, 1.27) | 1.28<br>(1.24,1.32)  | 0.93<br>(0.87, 1.00) | 1.02<br>(0.96, 1.08) | 0.88<br>(071, 1.09)  | 0.98<br>(0.83, 1.15) |

\* Adjusted for age at diagnosis, race and ethnicity, geographic area, marital status, cancer stage, treatment type and socio-economic status

\*\* Inverse probability of treatment weighting

eTable3: Association between ADT and diagnosis of Alzheimer’s or dementia (treatment type subgroups). Hazard ratio represent the comparison between patients with ADT (within 24 months of diagnosis) and those without ADT - sub groups of treatment type

| Model                                       | Treatment type        |                      |                           |                      |                                |                      |
|---|-----------------------|----------------------|---------------------------|----------------------|--------------------------------|----------------------|
|   | Surgery <sup>\$</sup> |                      | Radiation <sup>\$\$</sup> |                      | Chemotherapy <sup>\$\$\$</sup> |                      |
|   | Alzheimer’s HR(CI)    | Dementia HR (CI)     | Alzheimer’s HR(CI)        | Dementia HR (CI)     | Alzheimer’s HR(CI)             | Dementia HR (CI)     |
| <b>Unadjusted</b>                           |                       |                      |                           |                      |                                |                      |
|   | 1.31<br>(1.22, 1.41)  | 1.36<br>(1.28, 1.43) | 1.54<br>(1.48, 1.60)      | 1.57<br>(1.52, 1.62) | 2.02<br>(1.34, 3.05)           | 1.83<br>(1.36, 2.46) |
| <b>Propensity score adjusted * (IPTW)**</b> |                       |                      |                           |                      |                                |                      |
|   | 0.92<br>(0.85, 0.98)  | 1.16<br>(1.10, 1.23) | 1.22<br>(1.17, 1.27)      | 1.21<br>(1.67, 1.24) | 1.44<br>(0.96, 2.16)           | 1.24<br>(0.93, 1.65) |

\$ sub group of surgery (surgery alone or with radiation/chemo/ADT)

\$\$ sub group of radiation (radiation alone or with chemo/ADT)

\$\$\$ sub group of chemotherapy (chemotherapy alone or with ADT)

\* Adjusted for age at diagnosis, race and ethnicity, geographic area, marital status, comorbidity score, cancer stage, and socio-economic status;

\*\* Inverse probability of treatment weighting

eTable4: Association between ADT and diagnosis of Alzheimer’s or dementia (cancer stage). Hazard ratio represent the comparison between patients with ADT (within 24 months of diagnosis) and those without ADT – localized vs. advanced stage

| Model                                       | Cancer stage           |                      |                        |                      |
|---|------------------------|----------------------|------------------------|----------------------|
|   | Localized              |                      | Advanced               |                      |
|   | Alzheimer’s<br>HR (CI) | Dementia<br>HR (CI)  | Alzheimer’s<br>HR (CI) | Dementia<br>HR (CI)  |
| <b>Unadjusted</b>                           |                        |                      |                        |                      |
|   | 1.58<br>(1.52, 1.63)   | 1.62<br>(1.58, 1.67) | 1.45<br>(1.35, 1.54)   | 1.51<br>(1.44, 1.59) |
| <b>Propensity score adjusted * (IPTW)**</b> |                        |                      |                        |                      |
|   | 1.15<br>(1.10, 1.20)   | 1.22<br>(1.19, 1.26) | 1.08<br>(1.01, 1.16)   | 1.15<br>(1.09, 1.22) |

\* Adjusted for age at diagnosis, race and ethnicity, geographic area, marital status, comorbidity score, treatment type and socio-economic status;

\*\* Inverse probability of treatment weighting